Drugs / F007
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05178836 | Jan 2022 → Dec 2023 | relapsed/refractory diffuse large B-cell lymphoma | Shandong New Time Pharmaceutical Co., LTD | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05178836 ↗ |
| Route | Intravenous | “F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 14-day cycle for 8 cycles.” NCT05178836 ↗ |